MedicalResearch.com Interview with:
Steven A. Kaplan, M.D., FACS
Professor of Urology
Director, The Men’s Health Program
Icahn School of Medicine at Mount Sinai
MedicalResearch.com: What is the background for this study?
Response: PLUS is the first large-scale trial conducted in North America and Europe specifically designed to study the effects of mirabegron in controlling residual symptoms of urinary urgency and frequency in men with benign prostatic hyperplasia (BPH) using common agents such as tamsulosin (Flomax).
We explored whether mirabegron (Myrbetriq), an agent approved for the treatment of overactive bladder (OAB), improved patient outcomes when added to tamsulosin. This was a randomized, double-blind, placebo-controlled, multi-center study enrolling 715 male patients 40 years of age and older.